Banerjee Subhashis sold $5K of ARTV

Banerjee Subhashis (Chief Medical Officer) sold 429 shares of Artiva Biotherapeutics, Inc. (ARTV) at $12.00 on 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Banerjee Subhashis
Published Aug 20, 2026, 1:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
high confidence
Mentioned
$ARTV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

The transaction is a routine insider sale with limited market impact.

02

Market read

Low relevance; typical insider transaction with minimal price effect.

03

What to watch

Potential upcoming clinical data releases could change relevance of insider activity.

Relevance 2/10Novelty 4/10Timing: post-filing 2026-08-19

Background

Artiva Biotherapeutics filed a Form 4 reporting a $5K sale by its CMO under a pre‑arranged 10b5‑1 plan.

Company-level read

Ticker impact

$ARTVNeutralHigh confidence
Context

Form 4 disclosed Chief Medical Officer Banerjee Subhashis sold 429 shares for $5,148 via a 10b5-1 plan.

Expected impact

minimal impact, price likely unchanged

Evidence & confidence

Sale size is small relative to total holdings and market cap; typical for 10b5-1 plans.

Market effects

None; biotech sector not affected by a small insider transaction.

None; transaction is company‑specific.

None

Counterpoint

Even small insider sales can signal concerns; monitor upcoming disclosures.

Key entities

  • Artiva Biotherapeutics, Inc.

    Biotech firm developing therapies.

  • Banerjee Subhashis

    Chief Medical Officer of Artiva.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.